Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCEL
- Sponsors Abbott Laboratories
- 20 Oct 2017 Results assessing quality of life after everolimus-eluting stents or bypass surgery for treatment of left main disease, were published in the Journal of the American College of Cardiology.
- 31 Oct 2016 Primary endpoint has been met. (Composite measure of all-cause mortality, myocardial infarction (MI) or stroke)
- 31 Oct 2016 Results published in the New England Journal of Medicine